IBT
ITCI

International Biotechnology Trust’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

International Biotechnology Trust’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$16.5M Buy
317,856
+141,000
+80% +$8.21M 5.57% 4
2023
Q2 		$11.2M Sell
176,856
-81,000
-31% -$5.05M 3.4% 10
2023
Q1 		$14M Buy
257,856
+36,000
+16% +$1.74M 3.89% 7
2022
Q4 		$11.7M Hold
221,856
– – 3.62% 8
2022
Q3 		$10.3M Buy
221,856
+218,253
+6,058% +$11.4M 3.3% 8
2022
Q2 		$63.2K Sell
3,603
-47,353
-93% -$2.68M 0.66% 34
2022
Q1 		$20.9M Sell
50,956
-62,500
-55% -$3.25M 4.72% 4
2021
Q4 		$5.92M Buy
113,456
+34,000
+43% +$1.43M 1.32% 25
2021
Q3 		$2.96M Hold
79,456
– – 0.71% 32
2021
Q2 		$3.24M Hold
79,456
– – 0.86% 29
2021
Q1 		$2.7M Hold
79,456
– – 0.71% 28
2020
Q4 		$2.53M Buy
79,456
+54,656
+220% +$1.44M 0.69% 29
2020
Q3 		$637K Buy
24,800
+1,800
+8% +$41.1K 0.21% 48
2020
Q2 		$579K Hold
23,000
– – 0.19% 50
2020
Q1 		$352K Buy
+23,000
New +$500K 0.16% 53

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

International Biotechnology Trust's ITCI Position: Q3 2023 in Review

International Biotechnology Trust increased its Intra-Cellular Therapies Inc. (ITCI) stake by 80% in Q3 2023, buying an estimated $8.21M and bringing the position to 317,856 shares worth $16.5M. The position accounts for 5.57% of the portfolio, ranked #4.

International Biotechnology Trust first reported a position in ITCI in Q1 2020 and has held it in 15 quarters since. The position peaked at $20.9M in Q1 2022. 292 funds tracked by Wall St. Rank hold ITCI as of Q3 2023.

  • International Biotechnology Trust held 317,856 shares of Intra-Cellular Therapies Inc. worth $16.5M as of Q3 2023.
  • International Biotechnology Trust bought 141,000 Intra-Cellular Therapies Inc. shares in Q3 2023, an estimated $8.21M.
  • Intra-Cellular Therapies Inc. made up 5.57% of International Biotechnology Trust's portfolio in Q3 2023, its #4 holding.
  • International Biotechnology Trust first reported a position in Intra-Cellular Therapies Inc. in Q1 2020 and has held it in 15 quarters since.
  • International Biotechnology Trust's Intra-Cellular Therapies Inc. position peaked at $20.9M in Q1 2022.
  • 292 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2023.

Based on International Biotechnology Trust's 13F filing for Q3 2023, filed 14 Nov 2023.